Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of SPR720, Azithromycin, and Ethambutol Co-administration
NCT05966688Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Aug 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fobrepodacin in nontuberculous mycobacterial lung disease (5 arms), sponsored by Spero Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration, Time to Attain Maximum Plasma Concentration and 1 more. Started Aug 2023; status: completed.
02
Drugs
fobrepodacin
03
Conditions
nontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on NCT05966688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05966688.